// App-Quantinova.ai

9500 : Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma.

Researchers

Presenter

  • Reinhard Dummer

Principal Investigators

  • Paolo Antonio Ascierto

  • Ana Maria Arance Fernandez

  • Caroline Dutriaux

  • Michele Maio

  • Piotr Rutkowski

  • Michele Del Vecchio

  • Ralf Gutzmer

  • Mario Mandala

  • Luc Thomas

  • Ernesto Wasserman

  • James Ford

  • Marine Weill

  • L. Andres Sirulnik

  • Valentine Jehl

  • Viviana Bozon

  • Georgina V. Long

  • Keith Flaherty

Medical Centers

  • University Hospital of Essen, Essen, Germany

  • Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy

  • Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain

  • Hopital Saint-Andre, CHU de Bordeaux, Bordeaux, France

  • Medical Oncology and Immunotherapy, University Hospital of Siena, Siena, Italy

  • Maria Sklodowska-Curie Memorial Cancer Center & Institute of Oncology, Warsaw, Poland

  • Istituto Nazionale Tumori, Milano, Italy

  • Medizinische Hochschule Hannover, Hannover, Germany

  • Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy

  • Lyon 1 University Centre Hospitalier Lyon Sud, Pierre Benite, France

  • Novartis Pharmaceuticals Corporation, Florham Park, NJ

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Novartis AG, Basel, Switzerland

  • Array BioPharma, Boulder, CO

  • Melanoma Institute Australia and The University of Sydney, North Sydney, Australia

  • Massachusetts General Hospital Cancer Center, Boston, MA

Locations

  • Italy

  • Poland

  • Germany

  • Spain

  • Switzerland

  • Australia

  • United States

  • France

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

Biomarkers

  • N/A

Drug/Treatment

  • Binimetinib

  • dacarbazine Intravenous

Outcome

  • Unknown

Study Design

  • Randomized

  • Open Label

Phase

  • III

Study Id's

  • NCT01763164

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved